During the final session of the AACR Annual Meeting 2023, Program Committee Chair Robert H. Vonderheide, MD, DPhil, and three members of the Program Committee reviewed several significant highlights and important themes from the meeting.

A group of distinguished experts joined AACR Past President Lisa M. Coussens, PhD, FAACR, to discuss several complications of treating pregnant cancer patients, from the lack of randomized data about the safety and efficacy of cancer treatment in pregnant women to the increasingly complicated landscape of reproductive rights in the U.S.

Five leading researchers discussed new concepts in drug discovery, engineering, and delivery on the final day of the Annual Meeting. Evan A. Scott, PhD, reviewed the use of targeted nanocarriers for cell-selective cancer therapy.

Three experts discussed the evolution of phase I trials during an Annual Meeting symposium on Tuesday, April 18. “We must recognize that forward- and reverse-translation are complementary and phase I is the place to do it. The old linear model of moving forward and failing later is not serving us or our patients,” said Shivaani…

An expert panel, including session co-chairs Luis A. Diaz, MD, and Folakemi Odedina, PhD, discussed strategies to overcome disparities in oncology clinical trials during the Minorities in Cancer Research Scientific Symposium.

A panel of physician-scientists from the U.S. and sub-Saharan Africa discussed the challenges of global cancer care and opportunities to improve outcomes in lower- and middle-income countries during a symposium on the final day of the Annual Meeting. Sharmila Anandasabapathy, MD, moderated the session.

Three technology innovators, including session chair Tina Hernandez-Boussard, PhD, MPH, discussed how data-driven learning systems can be applied to different cancers to improve patient symptoms, outcomes, and overall care during an Annual Meeting symposium.